Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes
About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders, although the overall risk was low. These findings highlight the need for close monitoring of these conditions.
Corresponding Author: To contact the corresponding author, Rong Xu, PhD, email rxx@case.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.26327)
Editor’s ...